Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
Akshaya Sharon, Pharmacy student at JKK Nattraja College of Pharmacy, shared a post on LinkedIn:
“A major leap in hemophilia care – less frequent dosing, broader applicability.
On March 28, 2025, the U.S. FDA approved Qfitlia (fitusiran) – a novel prophylactic treatment for patients with Hemophilia A and B, with or without factor inhibitors.
This approval stands out not just as another drug launch – but as a shift in treatment strategy.
Unlike traditional therapies that replace missing clotting factors, Qfitlia works differently:
- It targets antithrombin, indirectly increasing thrombin generation
- This enhances clot formation without directly supplying FVIII or FIX
Why this matters:
- Extended dosing interval – administered once every 2 months
- Effective across both inhibitor and non-inhibitor patients
- Demonstrated ~70% reduction in annual bleeding rates
- Moves care closer to precision-guided dosing using companion diagnostics
The integration of the Innovance Antithrombin diagnostic test is especially notable – marking a step toward personalized prophylaxis, where dosing is adjusted based on biological response rather than fixed schedules.
However, innovation comes with caution.
Qfitlia carries serious safety considerations:
- Risk of thrombotic events
- Liver toxicity monitoring required
- Potential gallbladder complications
This approval reflects a broader trend in therapeutics:
- Moving from replacement therapies – pathway modulation
- From frequent dosing – long-acting precision care
For clinicians and researchers, this opens new discussions around balancing efficacy with safety, especially in long – term management.
For patients, it offers something equally powerful – convenience with improved outcomes.
A promising step forward in redefining hemophilia management.”
Stay updated on all scientific updates with Hemostasis Today.
-
Jun 4, 2026, 05:42Subramamyam Penubaku: Early Recognition and Risk-Based Management of Acute Pulmonary Embolism
-
Jun 4, 2026, 05:30Raghavendra Rao: Early Endothermal Ablation and Contemporary Management of Superficial Venous Thrombosis
-
Jun 4, 2026, 05:18Fouad Mikhail: Mechanical Thrombectomy and Anticoagulation in Intermediate-Risk Pulmonary Embolism
-
Jun 3, 2026, 17:18Giacomo Rossi: Cysteine and Gut Health – MIT Finds the Switch
-
Jun 3, 2026, 17:00Amin Ullah: Presence of RBCs of Unequal Sizes in a Peripheral Blood Smear – Anisocytosis of RBC
-
Jun 3, 2026, 16:59Jean Connors: Discussing Cancer-Associated Thrombosis at the Japanese Society of Thrombosis and Hemostasis
-
Jun 3, 2026, 16:54Ayush Bhowmik: Failed Drug Became the World’s Most Widely Used Blood Thinner
-
Jun 3, 2026, 16:13Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
-
Jun 3, 2026, 16:08Pedro Henrique Las Casas: How Anticoagulant Agents and Quercetin Influence Cancer Cell Procoagulant Activity